NCT01316016

Brief Summary

The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for not_applicable obesity

Timeline
Completed

Started Apr 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 16, 2011

Completed
Last Updated

March 16, 2011

Status Verified

February 1, 2011

Enrollment Period

10 months

First QC Date

March 15, 2011

Last Update Submit

March 15, 2011

Conditions

Obesity

Keywords

obesityglucose intolerancecholesterolblood pressure

Study Arms (1)

Rose hip

EXPERIMENTAL
Dietary Supplement: Rose hip

Interventions

Rose hipDIETARY_SUPPLEMENT

40 g of rose hip powder daily for 6 weeks.

Rose hip

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI \> 30
  • willingness to participate in the study
  • willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

You may not qualify if:

  • diabetes
  • previous or ongoing insulin treatment
  • abnormal thyroid status
  • abnormal liver status
  • abnormal kidney status
  • known gastrointestinal disorder
  • pregnancy
  • suspected allergy to ingredients of the drinks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Endocrinology Clinic, Lund University Hospital

Lund, SE-22185, Sweden

Location

Related Publications (1)

  • Andersson U, Henriksson E, Strom K, Alenfall J, Goransson O, Holm C. Rose hip exerts antidiabetic effects via a mechanism involving downregulation of the hepatic lipogenic program. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E111-21. doi: 10.1152/ajpendo.00268.2010. Epub 2010 Oct 19.

    PMID: 20959531BACKGROUND

MeSH Terms

Conditions

ObesityGlucose Intolerance

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperglycemiaGlucose Metabolism DisordersMetabolic Diseases

Study Officials

  • Per Katzman, MD/PhD

    Lund University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 15, 2011

First Posted

March 16, 2011

Study Start

April 1, 2009

Primary Completion

February 1, 2010

Study Completion

January 1, 2011

Last Updated

March 16, 2011

Record last verified: 2011-02

Locations

SE(1)